NeuroSense Therapeutics Ltd.
NRSN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001875091
No open-market purchases or sales by NeuroSense Therapeutics Ltd. insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $285.7K in total; no superinvestor holds it.
Other share classesNRSNW
Q4 2024 vs. Q3 2024
How the institutions holding NeuroSense Therapeutics Ltd. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 7 | 13 | +6 |
| Shares | 225.4K | 646.5K | +421.2K (+186.9%) |
| Value | $285.9K | $775.8K | +$489.9K (+171.4%) |
New holders (7)
Institutions that held NeuroSense Therapeutics Ltd. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Morgan Stanley | 102,581 | $123.1K | 0.00% |
| Jane Street Group, LLC | 64,636 | $77.6K | 0.00% |
| HRT Financial LP | 64,390 | $77.0K | 0.00% |
| Stratos Wealth Partners, LTD. | 20,000 | $24.0K | 0.00% |
| Two Sigma Securities, LLC | 15,017 | $18.0K | 0.00% |
| Warberg Asset Management LLC | 10,700 | $12.8K | 0.00% |
| SBI Securities Co., Ltd. | 175 | $210 | 0.00% |
Sold out (1)
Institutions that held NeuroSense Therapeutics Ltd. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Cantor Fitzgerald, L. P. | 79,492 | $101.0K |